1. A compound of Formula I



I

wherein R, R_2, and R_3 are hydrido;

wherein R_1 is selected from the group consisting of alkyl and alkoxy;

wherein R_4 is selected from the group consisting of

hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl,



,



;

wherein n is 0-6, inclusive;

wherein R_{15} is selected from the group consisting of hydrido, alkyl, hydroxyalkyl, alkoxyalkyl, aryl, alkoxyalkyl, alkylaminoalkyl, and N-aryl-N-alkylaminoalkyl;

wherein R_{17} is selected from the group consisting of alkyl, cycloalkyl, aralkyl;

wherein R_{16} is selected from the group consisting of hydrido, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, guanidinylalkyl, carboxyalkyl, hydroxyalkyl, alkoxyalkyl, aralkoxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, and



;

wherein R_{20} is alkyl;

wherein R_{23} is hydrido, alkyl, and aralkyl; and

wherein R_{24} is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkylaminoalkyl, aralkoxyalkyl, alkoxyalkyl, aryl, aralkyl, heterocyclyl, and heterocyclylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

2. The compound of claim 1 selected from the compounds and their pharmaceutically-acceptable salts, of the group consisting of

5-methyl-2[[(1R)-1phenylethyl]amino]-4H-3,1-benzoxazin-4-one;

N^{α}-(5-methyl-4-oxo-4H-3,1-benzoxazin-2-yl)-N^{ε}-[(phenylmethoxy)carconyl]-L-lysine, 1,1-dimethylethyl ester;

N-(5-methyl-4-oxo-4H-3,1-benzoxazin-2-yl)-L-phenylalanine, methyl ester;

N-(5-methyl-4-oxo-4H-3,1-benzoxazin-2-yl)-L-tryptohphan, methyl ester;

N-(5-methyl-4-oxo-4H-3,1-benzoxazin-2-yl)-L-tryptophan, 1,1-dimethyl ester;

2-[[2-methoxy-(1S)-(1-phenyllmethyl)ethyl]amino]-5-methyl-4H-3,1-benzoxazin-4-one;

3,5-diiodo-N-(5-methyl-4-oxo-4H-3,1-benzoxazin-2-yl)-L-tyrosine, methyl ester;

N-(5-methyl-4-oxo-4H-3,1-benzoxazin-2-yl)-O-methyl-L-tyrosine, methyl ester;

N-(5-methyl-4-oxo-4H-3,1-benzoxazin-2-yl)-L-phenylglycine, 1,1-dimethylethyl ester;

αS-[(5-methyl-4-oxo-4H-3,1-benzoxazin-2-yl)amino]-4-methoxy-N-methyl-N-(phenylmethyl)benzenepropanamide;

5-methoxy-2-[[(1R)-1-phenylethyl]amino]-4H-3,1-benzoxazin-4-one; and

N-[5-methoxy-4-oxo-4H-3,1-benzoxazin-2-yl]-O-methyl-L-tyrosine, N-methyl-N-phenylmethylamide.

3. A pharmaceutical composition comprising a therapeutically-effective amount of a compound selected from a compound of claims 1 or 2 and a pharmaceutically-acceptable carrier or diluent.

4. A method of therapeutic treatment of a viral infection in a subject, said method comprising treating said subject with an effective amount of a compound according to claims 1 or 2.

5. The method of claim 4 wherein the viral infection is caused by a herpesvirus.

6. The method of claim 6 wherein the viral infection is caused by CMV, HSV-1 or HSV-2.

7. A method of inhibiting a viral protease in a subject infected with a virus having said protease, said method comprising treating said subject with an effective amount of a compound according to claims 1 or 2.

8. The method of claim 7 wherein the viral infection is caused by a herpesvirus.

9. The method of claim 8 wherein the viral infection is caused by CMV, HSV-1 or HSV-2.